Relationship of Expression Between SOX11 and PAX5 in Pathological Tissue Specimens of Patients with Mantle Cell Lymphoma and Its Clinical Significance

JING Cai-xia, FENG Yu, CAO Xia, XU Cai-gang

Abstract

Investigate the expression of SRY-related HMG box 11 (SOX11) and paired box domain 5 (PAX5) in patients with mantle cell lymphoma (MCL) and analyze the relationship between them and their clinical significance.  Methods  Seventy-six formalin-fixed paraffin-embedded (FFPE) samples of patients who were diagnosed with MCL from January 2012 to August 2017 were collected．Fifty-six FFPE samples from patients with diffuse large B cell lymphoma (DLBCL), thirty-eight FFPE samples from patients with follicular lymphoma (FL) and nine FFPE samples from patients with Burkitt's lymphoma (BL) were used as control groups. Real-time quantitative PCR (qRT-PCR) and immunohistochemistry were used to detect the mRNA and protein expressions of SOX11 and PAX5. The association between expressions of SOX11 and PAX5 in patients with MCL was analyzed. On the basis of the median H score of SOX11 and PAX5 protein expressions in patients with MCL, they were divided into high and low expression group, and the relationship between the different groups and patients’ clinical characteristics and prognosis were analyzed.  Results  The different mRNA expression levels of SOX11 and PAX5 in different lymphoma tissues were statistically significant (P<0.01). The mRNA expression levels of SOX11 and PAX5 in MCL group were higher than those of the control groups, and the differences of those between MCL and DLBCL or FL were statistically significant (P<0.01). However, the differences of those between MCL and BL were not significant (P>0.05). The expression level of SOX11 protein was also higher than those of the control groups (P<0.000 1). However, there was no significant difference in PAX5 protein expression level between the MCL group and the control group, nor the expression levels of SOX11 and PAX5 genes and proteins among the control groups (P>0.05). By analyzing the samples from patients with MCL, we observed a positive relevance between SOX11 and PAX5 both in mRNA expression level (rs=0.714, P<0.000 1) and protein expression level (G=0.407, P=0.01). There was no difference in clinical characteristics and overall survival between the high and low expression group.  Conclusion  In MCL, there was a positive relevance between the expressions of SOX11 and PAX5. The expression of SOX11 or PAX5 alone has no significant effect on the prognostic stratification of MCL patients.

 

Keywords: Mantle cell lymphoma, SOX11, PAX5, Prognosis

 

Full Text:

PDF


References


BEA S， AMADOR V. Role of SOX11 and genetic events cooperating with cyclin D1 in Mantle Cell Lymphoma. Curr Oncol Rep， 2017， 19(6): 43[2020-01-12]. https://doi.org/10.1007/s11912-017-0598-1.

EK S， DICTOR M， JERKEMAN M， et al. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood，2008，111(2): 800–805.

MOZOS A， ROYO C， HARTMAMM E， et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica，2009，94(11): 1555–1562.

BEEKMAN R， AMADOR V， CAMPO E. SOX11, a key oncogenic factor in mantle cell lymphoma. Curr Opin Hematol，2018，25(4): 299–306.

NYGREN L， BAUMGARTNER W S， KLIMKOWSKA M， et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood，2012，119(18): 4215–4223.

NORDSTROM L， SERNBO S， EDEN P， et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma—a Nordic Lymphoma Group study. Br J Haematol，2014，166(1): 98–108.

AUKEMA S M， HOSTER E， ROSENWALD A， et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood，2018，131(4): 417–420.

TEO A E， CHEN Z， MIRANDA R N， et al. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1. Leukemia，2016，30(3): 580–593.

VEGLIANTE M C， PALOMERO J， PEREZ-GALAN P， et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood，2013，121(12): 2175–2185.

SABATTINI E， BACCI F， SAGRAMOSO C， et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica，2010，102(3): 83–87.

VARGHESE F， BUKHARI A B， MALHOTRA R， et al. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One， 2014， 9(5): e96801[2020-01-12]. https://doi.org/10.1371/journal. pone.0096801.

BYDOUN M， STEREA A， LIPTAY H， et al. S100A10, a novel biomarker in pancreatic ductal adenocarcinoma. Mol Oncol，2018， 12(11): 1895–1916.

MORRISON A M， JAGER U， CHOTT A， et al. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood，1998，92(10): 3865–3878.

COBALEDA C， JOCHUM W， BUSSLINGER M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature，2007，449(7161): 473–477.

SADAKANE Y， ZAITSU M， NISHI M， et al. Expression and production of aberrant PAX5 with deletion of exon 8 in B-lineage acute lymphoblastic leukaemia of children. Br J Haematol，2007，136(2): 297–300.


Refbacks

  • There are currently no refbacks.